Bronnen:
- Porselijn L, Huiskes E, Oldert G, et al. Detection of platelet autoantobosies revisited to identify immmune thrombocytopenia Blood. 2015;126:1142.,Porcelijn L, Huiskes E, Schipperus M, et al. Lack of detectable platelet autoantibodies is correlated with nonresponsivenes to rituximab treatment in ITP patients. Blood. 2017;129:338.,Amini S. STIP-studie: het staken van trombopeïtinereceptoragonisten bij patiënten met chronische immuungemedieerde thrombocytopenie. Ned Tijdschr Hematol. 2018;15:233-5.,Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371:395-403.,Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-47.,Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:641-8.,Sarpatwari A, Provan D, Ergou S, et al. Autologous In-111-labelled platelet sequestration studies in patients with primary ITP prior to spelectomy: a report from the UK ITP Registry. Br J Haematol. 2010;151:477-87.,Najean Y, Dufour V, Rain JD, Toubert ME. The site of platelet destruction in thrombocytopenic purpura as a predictive index of the efficacy of splenectomy. Br J Haematol. 1991;79:271-6.